Clinical trial
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
NCT02049905 · ImmunityBio, Inc., Industry · Completed
Key facts
| NCT number | NCT02049905 |
|---|---|
| Title | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas |
| Official title | A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy |
| Lead sponsor | ImmunityBio, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma |
| Intervention type | Drug |
| Interventions | Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide) |
| Enrollment | 433 |
| Start date | Jan 1, 2014 |
| Primary completion | May 1, 2017 |
| Completion | May 1, 2017 |
| First posted | Jan 30, 2014 |
| Last update posted | Jun 13, 2024 |
| Countries | Australia, Canada, Chile, Denmark, France, Hungary, Israel, Italy, Netherlands, Poland, Russia, Spain and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: